PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates

References

• Pico de Coaña Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015;21(8):482–14. doi:10.1016/j.molmed.2015.05.005.
   PubMed Web of Science ®Google Scholar
• Pico de Coaña Y, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nystrom M, Edback U, Brage SE, Lundqvist A, Masucci GV, et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget. 2017;8(13):21539–21553. doi:10.18632/oncotarget.15368.
   PubMedGoogle Scholar
• Weiss SA, Wolchok JD, Sznol M. Immunotherapy of melanoma: facts and hopes. Clin Cancer Res. 2019 Mar 28. doi:10.1158/1078-0432.CCR-18-1550.
   Web of Science ®Google Scholar
• Seo H, Jeon I, Kim B-S, Park M, Bae E-A, Song B, Koh C-H, Shin K-S, Kim I-K, Choi K, et al. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. Nat Commun. 2017;8:15776. doi:10.1038/ncomms15776.
   PubMed Web of Science ®Google Scholar
• Park IH, Yang HN, Lee KJ, Kim T-S, Lee ES, Jung S-Y, Kwon Y, Kong S-Y, Hae Park I, Na Yang H, et al. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. Oncotarget. 2017;8(20):32722–32730. doi:10.18632/oncotarget.16281.
   PubMedGoogle Scholar
• Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol. 2012;144(3):250–268. doi:10.1016/j.clim.2012.06.003.
   PubMed Web of Science ®Google Scholar
• Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16–25. doi:10.1038/s41416-018-0333-1.
   PubMed Web of Science ®Google Scholar
• Umansky V, Adema GJGJ, Baran J, Brandau S, van Ginderachter JAJA, Hu X, Jablonska J, Mojsilovic S, Papadaki HAHA, Pico de Coaña Y, et al. Interactions among myeloid regulatory cells in cancer. Cancer Immunol Immunother. 2019;68(4):645–660. doi:10.1007/s00262-018-2200-6.
   PubMed Web of Science ®Google Scholar
• Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010;70(11):4335–4345. doi:10.1158/0008-5472.CAN-09-3767.
   PubMed Web of Science ®Google Scholar
• Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 2018;9:398. doi:10.3389/fimmu.2018.00398.
   PubMed Web of Science ®Google Scholar
• Pico de Coaña Y, Poschke I, Gentilcore G, Mao Y, Nystrom M, Hansson J, Masucci GV, Kiessling R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res. 2013;1(3):158–162. doi:10.1158/2326-6066.CIR-13-0016.
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJM, Liu YJ, MacPherson G, Randolph GJ, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116:16. doi:10.1182/blood-2010-02-258558.
   PubMedGoogle Scholar
• Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492. doi:10.3322/caac.21409.
   PubMed Web of Science ®Google Scholar
• Martens A, Wistuba-Hamprecht K, Foppen MG, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22(12):2908–2918. doi:10.1158/1078-0432.CCR-15-2412.
   PubMed Web of Science ®Google Scholar
• Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1(4):433–440. doi:10.1001/jamaoncol.2015.1184.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob -J-J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Jessurun CAC, Vos JAM, Limpens J, Luiten RM. Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Front Oncol. 2017;7(Sep). doi:10.3389/fonc.2017.00233.
   PubMedGoogle Scholar
• Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, et al. Early immune-related adverse events and association with outcome in advanced non–small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12(12):1798–1805. doi:10.1016/j.jtho.2017.08.022.
   PubMed Web of Science ®Google Scholar
• Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019;145(2):511–521. doi:10.1007/s00432-018-2819-x.
   PubMed Web of Science ®Google Scholar
• Okada N, Kawazoe H, Takechi K, Matsudate Y, Utsunomiya R, Zamami Y, Goda M, Imanishi M, Chuma M, Hidaka N, et al. Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study. Clin Ther. 2019;41(1):59–67. doi:10.1016/j.clinthera.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Sakakura K, Tada H, Kaira K, Oyama T, Chikamatsu K. Prognostic significance and population dynamics of peripheral monocytes in patients with oropharyngeal squamous cell carcinoma. Head & Neck. 2019;41(6):1880–1888. doi:10.1002/hed.25625
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Capone M, Grimaldi AM, Mallardo D, Simeone E, Madonna G, Roder H, Meyer K, Asmellash S, Oliveira C, et al. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. J Immunother Cancer. 2019;7(1):91. doi:10.1186/s40425-019-0569-1.
   PubMedGoogle Scholar
• Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, Ren S, Chen X, Zhou C. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung Cancer. 2019;130:76–83. doi:10.1016/j.lungcan.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Ma J, Kuzman J, Ray A, Lawson BO, Khong B, Xuan S, Hahn AW, Khong HT. Neutrophil-to-lymphocyte ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. Sci Rep. 2018;8(1):4044. doi:10.1038/s41598-018-22425-3.
   PubMedGoogle Scholar
• Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res. 2014;20(6):1601–1609. doi:10.1158/1078-0432.CCR-13-2508.
   PubMed Web of Science ®Google Scholar
• Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes. 2017;10(1):1–4. doi:10.1186/s13104-016-2335-5.
   PubMedGoogle Scholar
• Nakamura Y, Tanaka R, Maruyama H, Ishitsuka Y, Okiyama N, Watanabe R, Fujimoto M, Fujisawa Y. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn J Clin Oncol. 2019;49(5):431–437. doi:10.1093/jjco/hyy201.
   PubMed Web of Science ®Google Scholar
• Tallerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de Coaña Y, Madonna G, Palella E, Wolodarski M, et al. IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncoimmunology. 2017;6(2). doi:10.1080/2162402X.2016.1261242.
   Web of Science ®Google Scholar
• Subrahmanyam PB, Dong Z, Gusenleitner D, Giobbie-Hurder A, Severgnini M, Zhou J, Manos M, Eastman LM, Maecker HT, Hodi FS, et al. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer. 2018;6(1):18. doi:10.1186/s40425-018-0328-8.
   PubMedGoogle Scholar
• Sattui S, de la Flor C, Sanchez C, Lewis D, Lopez G, Rizo-Patron E, White AC Jr, Montes M. Cryopreservation modulates the detection of regulatory T cell markers. Cytom B Clin Cytom. 2012;82(1):54–58. doi:10.1002/cyto.b.20621.
   PubMedGoogle Scholar
• Florek M, Schneidawind D, Pierini A, Baker J, Armstrong R, Pan Y, Leveson-Gower D, Negrin R, Meyer E. Freeze and thaw of CD4+CD25+Foxp3+ regulatory T cells results in loss of CD62L expression and a reduced capacity to protect against graft-versus-host disease. PLoS One. 2015;10(12):e0145763. doi:10.1371/journal.pone.0145763.
   PubMed Web of Science ®Google Scholar
• Grutzner E, Stirner R, Arenz L, Athanasoulia AP, Schrodl K, Berking C, Bogner JR, Draenert R. Kinetics of human myeloid-derived suppressor cells after blood draw. J Transl Med. 2016;14(1):2. doi:10.1186/s12967-015-0755-y.
   PubMedGoogle Scholar
• Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods. 2012;381(1–2):14–22. doi:10.1016/j.jim.2012.04.004.
   PubMed Web of Science ®Google Scholar
• Trellakis S, Bruderek K, Hutte J, Elian M, Hoffmann TK, Lang S, Brandau S. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun. 2013;19(3):328–336. doi:10.1177/1753425912463618.
   PubMed Web of Science ®Google Scholar
• Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, Maubec E, Marinho E, Scheer-Senyarich I, Cremer I, Avril M-F, et al. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages Dieli F, editor. PLoS One. 2013;8(10):e76928. doi:10.1371/journal.pone.0076928.
   PubMed Web of Science ®Google Scholar
• Holthaus L, Lamp D, Gavrisan A, Sharma V, Ziegler A-G, Jastroch M, Bonifacio E. CD4+ T cell activation, function, and metabolism are inhibited by low concentrations of DMSO. J Immunol Methods. 2018;463:54–60. doi:10.1016/J.JIM.2018.09.004.
   PubMed Web of Science ®Google Scholar
• Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167–2176. doi:10.1182/blood-2009-08-238469.
   PubMed Web of Science ®Google Scholar
• Picard E, Godet Y, Laheurte C, Dosset M, Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L, et al. Circulating NKp46 + natural killer cells have a potential regulatory property and predict distinct survival in non-small cell lung cancer. Oncoimmunology. 2019;8(2):1–13. doi:10.1080/2162402X.2018.1527498.
   Web of Science ®Google Scholar
• da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014;2(5):410–422. doi:10.1158/2326-6066.CIR-13-0171.
   PubMed Web of Science ®Google Scholar
• Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre J-R, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, et al. IL-21–induced MHC class II + NK cells promote the expansion of human uncommitted CD4 + central memory T cells in a macrophage migration inhibitory factor–dependent manner. J Immunol. 2016;197(1):85–96. doi:10.4049/jimmunol.1501147.
   PubMed Web of Science ®Google Scholar
• Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Brage SESE, Schultz I, Hansson J, Masucci G, Lundqvist A, Kiessling R, et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res. 2013;73(13):3877–3887. doi:10.1158/0008-5472.CAN-12-4115.
   PubMed Web of Science ®Google Scholar
• Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E, Speiser DE. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63(3):247–257. doi:10.1007/s00262-013-1508-5.
   PubMed Web of Science ®Google Scholar
• Pico de Coaña Y, Masucci G, Hansson J, Kiessling R. Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. Cancer Immunol Immunother. 2014;63(9):977–983. doi:10.1007/s00262-014-1570-7.
   PubMed Web of Science ®Google Scholar
• Laupéze B, Fardel O, Onno M, Bertho N, Drénou B, Fauchet R, Amiot L. Differential expression of major histocompatibility complex class Ia, Ib and II molecules on monocytes and monocyte-derived dendritic and macrophagic cells. Hum Immunol. 1999;60(7):591–597. doi:10.1016/S0198-8859(99)00025-7.
   PubMed Web of Science ®Google Scholar
• Hornell TMC, Beresford GW, Bushey A, Boss JM, Mellins ED. Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor. J Immunol. 2003;171(5):2374–2383. doi:10.4049/jimmunol.171.5.2374.
   PubMed Web of Science ®Google Scholar
• Voskamp AL, Prickett SR, Mackay F, Rolland JM, O’Hehir RE, Class MHC. II expression in human basophils: induction and lack of functional significance Ryffel B, editor. PLoS One. 2013;8(12):e81777. doi:10.1371/journal.pone.0081777.
   PubMed Web of Science ®Google Scholar
• Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, Pan F, Topalian SL. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1). doi:10.1186/s40425-019-0770-2.
   Web of Science ®Google Scholar
• Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007;81(3):584–592. doi:10.1189/jlb.0806510.
   PubMed Web of Science ®Google Scholar
• Belge K-U, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002;168(7):3536–3542. doi:10.4049/jimmunol.168.7.3536.
   PubMed Web of Science ®Google Scholar
• Skrzeczyńska-Moncznik J, Bzowska M, Loseke S, Grage-Griebenow E, Zembala M, Pryjma J. Peripheral blood CD14high CD16+ monocytes are main producers of IL-10. Scand J Immunol. 2008;67(2):152–159. doi:10.1111/j.1365-3083.2007.02051.x.
   PubMed Web of Science ®Google Scholar
• Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci. 2015;112(19):6140–6145. doi:10.1073/pnas.1417320112.
   PubMed Web of Science ®Google Scholar
• Lee J, Tam H, Adler L, Ilstad-Minnihan A, Macaubas C, Mellins ED. The MHC class II antigen presentation pathway in human monocytes differs by subset and is regulated by cytokines. PLoS One. 2017;12(8). doi:10.1371/journal.pone.0183594.
   Web of Science ®Google Scholar
• Neo SY, Yang Y, Julien R, Ma R, Chen X, Chen Z, Tobin NP, Blake E, Seitz C, Thomas R, et al. CD73 immune checkpoint defines regulatory NK-cells within the tumor microenvironment. J Clin Invest. 2019 Nov 26. doi:10.1172/JCI128895.
   Web of Science ®Google Scholar
• Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemom. 2002;16(3):119–128. doi:10.1002/cem.695.
   Web of Science ®Google Scholar
• Dutta M, Subramani E, Taunk K, Gajbhiye A, Seal S, Pendharkar N, Dhali S, Ray CD, Lodh I, Chakravarty B, et al. Investigation of serum proteome alterations in human endometriosis. J Proteomics. 2015;114:182–196. doi:10.1016/J.JPROT.2014.10.021.
   PubMed Web of Science ®Google Scholar
• Wheelock ÅM, Wheelock CE. Trials and tribulations of ‘omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol Biosyst. 2013;9(11):2589. doi:10.1039/c3mb70194h.
   PubMedGoogle Scholar
• Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862. doi:10.1371/journal.pone.0051862.
   PubMed Web of Science ®Google Scholar